3 results
Primary objective: To evaluate the safety and tolerability of SOBI003 at different dose levels.Secondary objectives:1. To characterize the pharmacokinetic (PK) properties of SOBI003 following single and repeated administration by the use of non-…
To compare tisagenlecleucel treatment strategy to SOC treatment strategy with respect to delaying the composite event of disease progression / stable disease at or after the week 12 assessment; or death at any time.
This single arm, multi-center, phase II study will determine the efficacy and safety of tisagenlecleucel in adult patients with FL who failed at least 2 prior systemic therapies, including an anti-CD20 antibody (e.g. rituximab) and an alkylating…